OncoMatch/Clinical Trials/NCT05628870
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
Is NCT05628870 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HRS-1358 for breast cancer.
Treatment: HRS-1358 — The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy or combination with Dalpiciclib Isethionate Tablets in patients with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: endocrine therapy — metastatic or advanced
Cannot have received: similar drugs
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ functions as defined
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05628870 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior similar drugs disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages